<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62103">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01944436</url>
  </required_header>
  <id_info>
    <org_study_id>LBD-312-2006</org_study_id>
    <nct_id>NCT01944436</nct_id>
  </id_info>
  <brief_title>A Genetic and Perfusion Study of Response to Cognitive Enhancers in Lewy Body Disease</brief_title>
  <official_title>Lewy Body Spectrum Disorders: Investigating Neuropsychiatric Benefit and Adverse Effects in Response to Cholinesterase Inhibitors Using Genetics and Brain SPECT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lewy body spectrum disorders are a common group of neurodegenerative diseases that cause
      memory loss, behavioural and motor disabilities that impair quality of life. Cognitive
      enhancers help people afflicted with these conditions. However, some people do not benefit
      from this treatment, while others experience serious side effects. Side effects and poor
      response lead to hospitalization and early institutionalization. Pharmacogenomics, the study
      of how DNA variation can influence drug effects, will be combined with functional changes in
      brain imaging in response to cognitive enhancers in patients with Lewy body disease. The
      goal is to develop a predictive test that can be administered in the clinic to aid
      physicians' choice of initial medication. This can reduce health care costs and improve
      treatment to Canadians suffering from these devastating disorders.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Change from baseline in perfusion brain SPECT at 6 months</measure>
    <time_frame>0 and 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in neuropsychological assessment scores at 6 months</measure>
    <time_frame>0 and 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Volumetric Brain MRI</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Lewy Body Disease</condition>
  <arm_group>
    <arm_group_label>Parkinson's Disease Dementia</arm_group_label>
    <description>Participants in the Parkinson's Disease Dementia group:
Must be taking a stable parkinsonian medication
Must have a diagnosis of clinically definite Parkinson's disease &gt;1 year prior to cognitive deficit with at least two of the following symptoms: asymmetric resting tremor, rigidity or bradykinesia, and definite motor response to dopaminergic agents.
Response to cholinesterase inhibitor over a period of six months will be monitored.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dementia with Lewy Bodies</arm_group_label>
    <description>Participants in the Dementia with Lewy Bodies group:
Diagnosis of clinically probable or possible Dementia with Lewy bodies with at least 1 of the following: Marked fluctuations in cognition, visual hallucinations or spontaneous parkinsonism.
Response to cholinesterase inhibitor over a period of six months will be monitored.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholinesterase Inhibitors (Rivastigmine, Aricept, Galantamine)</intervention_name>
    <arm_group_label>Parkinson's Disease Dementia</arm_group_label>
    <arm_group_label>Dementia with Lewy Bodies</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Functional and tag SNPs in the following genes will be assessed:

      acetylcholinesterase (ACHE); butyrylcholinesterase (BCHE); M1 muscarinic receptor (CHRM1);
      alpha7-nicotinic receptor (CHRNA7); Apolipoprotein E (ApoE); Cytochrome P450 2D6 (protein:
      CYP2D6 /gene: CYP2D6); CYP3A4; all genes related to blood pressure disregulation, white
      matter changes found on neuroimaging, and genes related to Lewy Body Spectrum disorders in
      general.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Ontario, Canada.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inclusion criteria for patients with a Lewy body spectrum disorder includes: age &gt; 50
             years; and mild-moderate dementia (Mini-Mental State Exam [MMSE] &gt; 9); contact on at
             least four of seven days/week with a responsible caregiver; Hoehn &amp; Yahr stage â‰¤ 4.

        Exclusion Criteria:

          -  age &lt; 50; Severe dementia (MMSE &lt; 9); contact &lt; 4 days a week with a responsible
             caregiver; Hoehn &amp; Yahr stage &gt; 4.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michelle A Messner, B.A.</last_name>
    <phone>416-480-6100</phone>
    <phone_ext>1620</phone_ext>
    <email>michelle.messner@sunnybrook.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kayla Sherborn, B.A.</last_name>
    <phone>416-480-6100</phone>
    <phone_ext>1620</phone_ext>
    <email>kayla.sherborn@sunnybrook.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Messner</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>1620</phone_ext>
      <email>michelle.messner@sunnybrook.ca</email>
    </contact>
    <contact_backup>
      <last_name>Kayla Sherborn</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>1620</phone_ext>
      <email>kayla.sherborn@sunnybrook.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Mario Masellis, MSc, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 12, 2013</lastchanged_date>
  <firstreceived_date>September 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sunnybrook Health Sciences Centre</investigator_affiliation>
    <investigator_full_name>Dr. Mario Masellis</investigator_full_name>
    <investigator_title>Clinician-Scientist</investigator_title>
  </responsible_party>
  <keyword>Pharmacogenomics</keyword>
  <keyword>Dementia with Lewy bodies</keyword>
  <keyword>Adverse events</keyword>
  <keyword>Polymorphisms</keyword>
  <keyword>Acetylcholinesterase</keyword>
  <keyword>Parkinson's Disease Dementia</keyword>
  <keyword>Cognitive enhancers</keyword>
  <keyword>Clinical efficacy</keyword>
  <keyword>Cytochrome P450</keyword>
  <keyword>Butyrylcholinesterase</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lewy Body Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholinesterase Inhibitors</mesh_term>
    <mesh_term>Galantamine</mesh_term>
    <mesh_term>Rivastigmine</mesh_term>
    <mesh_term>Nootropic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
